NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02367040,Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),https://clinicaltrials.gov/study/NCT02367040,CHRONOS-3,COMPLETED,"The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.",YES,"Lymphoma,Non-Hodgkin","DRUG: Copanlisib (Aliqopa, BAY80-6946)|DRUG: Placebo|DRUG: Rituximab","Progression Free Survival (PFS) Based on Independent Central Review., Progression-free survival (PFS) was defined as the time from randomization to progressive disease (PD) or death due to any cause, whichever was earlier according to the Lugano Classification and Response criteria in patients affected by Waldenström macroglobulinemia (kindly refer to the links in the Protocol section)., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years","Objective Response Rate (ORR), Objective response rate (ORR) was defined as the percentage of participants who have a best response rating over the whole duration of the study (i.e. until time of analysis of PFS) of complete response (CR) or partial response (PR) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) a response rating of CR, very good partial response (VGPR), PR, or minor response (MR) according to the Owen Criteria (kindly refer to the links in the Protocol section)., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Complete Response Rate (CRR), Complete response rate (CRR) was defined as the percentage of participants who had a best response rating over the whole duration of the study (i.e., until the time of analysis of PFS) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) a response rating of Complete Response according to the Owen Criteria (kindly refer to the links in the Protocol section)., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Duration of Response (DOR), Duration of response (DOR) was defined as the time (in days) from first observed tumor response Complete Response (CR), Very good partial response (VGPR), Partial Response (PR) or Minor Response (MR) until progression or death from any cause, whichever occurred earlier according to the Owen Criteria (kindly refer to the links in the Protocol section). Only patients with response in FAS were included in the analysis., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Disease Control Rate (DCR), Disease control rate was defined as the percentage of participants who had a best response rating as Complete Response (CR), Partial Response (PR) or stable disease (SD) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) as a response rating of CR, very good partial response (VGPR), PR, minor response (MR) or stable disease (SD) according to the Owen Criteria (kindly refer to the links in the Protocol section)., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Time to Progression (TTP), Time to progression (TTP) was defined as the time (days) from date of randomization to date of first observed disease progression according to the Lugano Classification and Response criteria in patients affected by Waldenström macroglobulinemia (kindly refer to the links in the Protocol section)., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Overall Survival (OS), Overall survival was defined as the time (in days) from randomization until death from any cause., From randomization up to approximately 7 years of follow-up.|Time to Deterioration in DRS-P (Disease-Related Symptoms - Physical) of at Least Three Points, as Measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) Questionnaire., Time to deterioration in DRS-P (Disease-Related Symptoms - Physical) of at least three points was defined as the time (in days) from randomization to DRS-P decline, progression, or death due to any reason, whichever occurred earlier. The Lymphoma Symptom Index-18 (FLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and was divided into a total score., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Time to Improvement in DRS-P (Disease-Related Symptoms - Physical) of at Least 3 Points, as Measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) Questionnaire., Time to improvement in DRS-P (Disease-Related Symptoms - Physical) was defined as the time (in days) from randomization to DRS-P improvement of at least three points. The Lymphoma Symptom Index-18 (FLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and was divided into a total score., From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years|Number of Participants With Treatment-emergent Adverse Events (TEAEs) at Primary Completion Date., Adverse events were considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication., Up to 30 days after end of treatment with study drug, data reporting cut-off at 5 years from the first participant randomization date|Number of Participants With Treatment-emergent Adverse Events (TEAEs) at 2-year Follow-up Cut-off Date., Adverse events were considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication., Up to 30 days after end of treatment with study drug, data reporting cut-off at 7 years from the first participant randomization date",,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,458,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",17067|2013-003893-29,2015-08-03,2020-08-31,2024-11-15,2015-02-20,2022-01-04,2025-01-17,"West Covina, California, 91790, United States|Ashland, Kentucky, 41101, United States|Louisville, Kentucky, 40207, United States|Bethesda, Maryland, 20817, United States|Las Vegas, Nevada, 89169, United States|MSK Basking Ridge, New Jersey, New Jersey, United States|MSK Bergen, New Jersey, New Jersey, United States|MSK Monmoth, New Jersey, New Jersey, United States|MSK Westchester, Harrison, New York, United States|MSK Commack, Long Island City, New York, United States|MSK Rockville Centre, Long Island City, New York, United States|New York, New York, 10021, United States|New York, New York, 10065, United States|Canton, Ohio, 44718, United States|Salt Lake City, Utah, 84106, United States|Spokane, Washington, 99208-1129, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, TBC, Argentina|Rosario, Santa Fe, S2000DEJ, Argentina|San Miguel de Tucumán, Tucuman, T4000, Argentina|Córdoba, X5000AOQ, Argentina|Ballarat, Victoria, 3350, Australia|Nedlands, 6009, Australia|Graz, Steiermark, 8036, Austria|Wien, 1090, Austria|Wien, 1130, Austria|Ottignies, 1340, Belgium|Passo Fundo, Rio Grande Do Sul, 99020-240, Brazil|Porto Alegre, Rio Grande Do Sul, 90850-170, Brazil|Barretos/SP, Sao Paulo, 14784-400, Brazil|Jaú, Sao Paulo, 17210-120, Brazil|São Paulo, Sao Paulo, 01234-030, Brazil|São Paulo, Sao Paulo, 08270-070, Brazil|Sao Paulo, 05403-000, Brazil|Sao Paulo, 05651-901, Brazil|Plovdiv, 4000, Bulgaria|Sofia, 1756, Bulgaria|Varna, 9010, Bulgaria|Temuco, Araucanía, 4800827, Chile|Fuzhou, Fujian, 350000, China|Guangzhou, Guangdong, 510000, China|Guangzhou, Guangdong, TBC, China|Wuhan, Hubei, 430079, China|Nanjing, Jiangsu, 210000, China|Suzhou, Jiangsu, 215000, China|Nanchang, Jiangxi, 330029, China|Changchun City, Jilin, 130061, China|Shengyang, Liaoning, 110042, China|Chengdu, Sichuan, 610041, China|Urumqi, Xinjiang, 830011, China|Hangzhou, Zhejiang, 310000, China|Hangzhou, Zhejiang, 310022, China|Beijing, 100000, China|Beijing, 100050, China|Beijing, 100083, China|Beijing, 100730, China|Chongqing, 400030, China|Chongqing, 400042, China|Shanghai, 200000, China|Shanghai, 200025, China|Shanghai, 200032, China|Tianjin, 300000, China|Tianjin, 300121, China|Medellin, Antioquia, 050034, Colombia|Bogota, Cundinamarca, 111511, Colombia|Montería, Córdoba, 230002, Colombia|Cali, Valle Del Cauca, 760032, Colombia|Bayonne, 64100, France|Brest, 29470, France|Metz Cedex 03, 57085, France|Nice Cedex 2, 6189, France|Pessac, 33600, France|Poitiers, 86021, France|Saint-Herblain, 44800, France|München, Bayern, 81377, Germany|Recklinghausen, Nordrhein-Westfalen, 45659, Germany|Halle, Sachsen-Anhalt, 6120, Germany|Dresden, Sachsen, 1307, Germany|Berlin, 10967, Germany|Athens, 106 76, Greece|Athens, 11527, Greece|Chaidari, 12462, Greece|Patras, 26500, Greece|Chai Wan, 0, Hong Kong|Hong Kong, MISSING, Hong Kong|Budapest, 1083, Hungary|Gyor, 9024, Hungary|Kaposvar, 7400, Hungary|Pecs, 7623, Hungary|Tatabanya, 2800, Hungary|Dublin, D07R2WY, Ireland|Dublin, D08NHY1, Ireland|Galway, H91YR71, Ireland|Udine, Friuli-Venezia Giulia, 33038, Italy|Genova, Liguria, 16132, Italy|Milano, Lombardia, 20133, Italy|Firenze, Toscana, 50134, Italy|Nagoya, Aichi, 464-8681, Japan|Nagoya, Aichi, 466-8650, Japan|Maebashi, Gunma, 371-8511, Japan|Kobe, Hyogo, 650-0047, Japan|Nankoku, Kochi, 783-8505, Japan|Sendai, Miyagi, 980-8574, Japan|Omura, Nagasaki, 856-8562, Japan|Kurashiki, Okayama, 710-8602, Japan|Hirakata, Osaka, 573-1191, Japan|Izumo, Shimane, 693-8501, Japan|Chuo-ku, Tokyo, 104-0045, Japan|Aomori, 030-8553, Japan|Fukuoka, 811-1395, Japan|Kumamoto, 860-8556, Japan|Niigata, 951-8566, Japan|Osaka, 545-8586, Japan|Yamagata, 990-9585, Japan|Seoul, Seoul Teugbyeolsi, 03722, Korea, Republic of|Seoul, Seoul Teugbyeolsi, 05505, Korea, Republic of|Seoul, Seoul Teugbyeolsi, 3080, Korea, Republic of|Busan, 49201, Korea, Republic of|Busan, 49241, Korea, Republic of|Hwasun Gun, 58128, Korea, Republic of|Seoul, 6351, Korea, Republic of|Kaunas, LT-50009, Lithuania|Cheras, 56000, Malaysia|Kota Kinabalu, 88586, Malaysia|Kuala Lumpur, 59100, Malaysia|Perak, 30450, Malaysia|Pulau Pinang, 10450, Malaysia|Selangor, 68000, Malaysia|Morelia, Michoacán, 58260, Mexico|Monterrey, Nuevo Leon, TBC, Mexico|Tauranga, 3112, New Zealand|Pasig city, 1605, Philippines|Taguig City, 1102, Philippines|Gdansk, 80-214, Poland|Gdynia, 81-519, Poland|Krakow, 30-727, Poland|Lublin, 20-090, Poland|Porto, 4200-072, Portugal|Porto, 4434-502, Portugal|Brasov, 500152, Romania|Bucuresti, 10825, Romania|Bucuresti, 20125, Romania|Bucuresti, 22328, Romania|Bucuresti, 30171, Romania|Cluj-Napoca, 400015, Romania|Craiova, 200143, Romania|Targu Mures, 540136, Romania|Chelyabinsk, 454048, Russian Federation|Irkutsk, 664035, Russian Federation|Kazan, 420029, Russian Federation|Kemerovo, 650066, Russian Federation|Kirov, 610027, Russian Federation|Novosibirsk, 630087, Russian Federation|Omsk, 644013, Russian Federation|St. Petersburg, 197022, Russian Federation|Volgograd, 400138, Russian Federation|Singapore, 119074, Singapore|Singapore, 168583, Singapore|Singapore, 169608, Singapore|Poprad, 058 01, Slovakia|George, Eastern Cape, 6530, South Africa|Johannesburg, Gauteng, 2013, South Africa|Majadahonda, Madrid, 28222, Spain|Barcelona, 08003, Spain|Barcelona, 08035, Spain|Barcelona, 8041, Spain|Madrid, 28041, Spain|Málaga, 29010, Spain|Salamanca, 37007, Spain|Changhua, 50006, Taiwan|Kaohsiung, 833, Taiwan|Tainan, 704, Taiwan|Taipei, 100, Taiwan|Taipei, 11217, Taiwan|Chiangmai, 50200, Thailand|Pathumthani, 10120, Thailand|Ankara, 6100, Turkey|Istanbul, 34093, Turkey|Izmir, 35100, Turkey|Kayseri, 38039, Turkey|Trabzon, 61080, Turkey|Cherkasy, 18009, Ukraine|Dnipro, 49102, Ukraine|Kyiv, 03022, Ukraine|Lviv, 79044, Ukraine|Vinnitsa, 21029, Ukraine|Ha Noi, 10000, Vietnam|Ho Chi Minh City, 70000, Vietnam","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/40/NCT02367040/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/40/NCT02367040/SAP_001.pdf"
